- Global Pharma News & Resources

Nordic Nanovector: Presentation at the Annual Congress of the European Association of Nuclear Medicine (EANM)

Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators at Orano Med will present data and analyses from preclinical studies with 212Pb-NNV003, a CD37 targeting alpha-radioimmunotherapy for the treatment of leukaemia and lymphoma at the 2019 Annual Congress of the European Association of Nuclear Medicine (12-16 October, Barcelona, Spain).

In the study, the efficacy of 212Pb-NNV003 was compared with ibrutinib in a disseminated mouse model using the ibrutinib-resistant cell line MEC-2. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that forms part of the standard of care for chronic lymphocytic leukaemia (CLL) and non-Hodkgin’s lymphoma (NHL), alongside chemotherapy and anti-CD20 antibody therapy.

The study showed that a single injection of 212Pb-NNV003 is safe and effective for the treatment of CD37-positive CLL and NHL in preclinical models, with promising efficacy in an ibrutinib-resistant CLL model.

Presentation details are as follows:

Targeted alpha therapy with 212Pb-NNV003 is efficient in treatment of ibrutinib-resistant chronic lymphocytic leukaemia in preclinical model

Authors:             A. Saidi, H. Heyerdahl, A.F. Maaland, J. Torgue, and J. Dahle

Session:             405 - M2M - Parallel Session: Antibody-Based Radionuclide Therapy

Abstract:            OP-134

Date / time:        Sunday 13 October, 14:30-14:41 CEST

The abstract book can be downloaded at

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762


International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571


About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at 

Editor Details

  • Company:
    • Nordic Nanovector
  • Name:
    • Nordic Nanovector
Last Updated: 10-Oct-2019